Histopathological study of the effects of Decalobanthus mammosus extract on liver necrosis in a tuberculosis mouse model

Authors

  • Rachmaniyah Rachmaniyah 1. Department of Science and Technology, Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia; 2. Department of Environmental Health, Poltekkes Kemenkes Surabaya, Surabaya, Indonesia Author https://orcid.org/0000-0001-6316-6874
  • Win Darmanto 1. Department of Science and Technology, Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia; 2. Instutute of Science, Technology and Health; ICME Jombang, Indonesia Author https://orcid.org/0000-0002-0488-403X
  • Dwi Winarni Department of Science and Technology, Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia Author https://orcid.org/0000-0001-7688-0620
  • Khambali Khambali Department of Environmental Health, Poltekkes Kemenkes Surabaya, Surabaya, Indonesia Author https://orcid.org/0000-0002-5085-0017
  • Fitri Rokhmalia Department of Environmental Health, Poltekkes Kemenkes Surabaya, Surabaya, Indonesia Author https://orcid.org/0009-0005-8410-2964

DOI:

https://doi.org/10.12923/cipms-2026-0025

Keywords:

Decalobanthus mammosus, tuberculosis, liver necrosis, histopathology, hepatoprotective

Abstract

Tuberculosis (TB) remains a global health problem, and hepatotoxicity associated with anti-TB therapy may complicate treatment. This study aimed to evaluate the effects of Decalobanthus mammosus tuber extract on liver histopathology in a Mycobacterium tuberculosis-infected mouse model. A post-test-only control group design was used involving 30 male Swiss albino mice allocated to five groups (n = 6 per group): a negative control group (K−; healthy, uninfected mice), an infected control group (K+; M. tuberculosis-infected mice without extract), and three treatment groups receiving D. mammosus extract at 200 mg/kg BW (P1), 400 mg/kg BW (P2), or 800 mg/kg BW (P3). Infection was induced intratracheally, followed by oral isoniazid therapy. Liver injury was assessed based on the mean number of necrotic cells across five microscopic fields per mouse and the ordinal Manja Roenigk score. The revised analysis treated the individual mouse as the experimental unit, used the Kruskal-Wallis test with Dunn’s post hoc test for the ordinal score, and applied negative binomial regression to necrotic-cell counts. The observed mean necrotic-cell counts were 1.4 ± 0.2 in K−, 8.7 ± 0.3 in K+, 1.2 ± 0.1 in P1, 6.4 ± 0.9 in P2, and 13.5 ± 1.2 in P3. Histopathological findings showed relatively preserved hepatic architecture in P1 and more extensive injury in P3. These findings indicate a non-linear tissue response to D. mammosus extract; however, inferential p-values and effect estimates should be inserted after reanalysis of the individual-mouse data using the specified statistical models.

References

1. World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization; 2024.

2. Yang H, Ruan X, Li W, Xiong J, Zheng Y. Global, regional, and national burden of tuberculosis and attributable risk factors for 204 countries and territories, 1990-2021: a systematic analysis for the Global Burden of Diseases 2021 study. BMC Public Health. 2024;24:3111. doi:10.1186/s12889-024-20664-w.

3. Zhuang X, Li L, Liu T, Zhang R, Yang P, Wang X, et al. Mechanisms of isoniazid and rifampicin-induced liver injury and the effects of natural medicinal ingredients: a review. Front Pharmacol. 2022;13:1037814. doi:10.3389/fphar.2022.1037814.

4. Sankar J, Chauhan A, Singh R, Mahajan D. Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement. Front Pharmacol. 2024;15:1441147. doi:10.3389/fphar.2024.1441147.

5. Kim JK, Park EJ, Jo EK. Itaconate, arginine, and gamma-aminobutyric acid: a host metabolite triad protective against mycobacterial infection. Front Immunol. 2022;13:832015. doi:10.3389/fimmu.2022.832015.

6. Tiegs G, Horst AK. TNF in the liver: targeting a central player in inflammation. Semin Immunopathol. 2022;44:445-59. doi:10.1007/s00281-022-00910-2.

7. Amaral EP, Namasivayam S, Queiroz ATL, Fukutani E, Hilligan KL, Aberman K, et al. BACH1 promotes tissue necrosis and Mycobacterium tuberculosis susceptibility. Nat Microbiol. 2024;9:120-35. doi:10.1038/s41564-023-01523-7.

8. Pandey B, Baral R, Kaundinnyayana A, Panta S. Promising hepato-protective agents from the natural sources: a study of scientific evidence. Egypt Liver J. 2023;13. doi:10.1186/s43066-023-00248-w.

9. Gajender, Mazumder A, Sharma A, Azad MAK. A comprehensive review of the pharmacological importance of dietary flavonoids as hepatoprotective agents. Evid Based Complement Alternat Med. 2023;2023:4139117. doi:10.1155/2023/4139117.

10. Qin Y, Zhao B, Deng H, Zhang M, Qiao Y, Liu Q, et al. Isolation and quantification of the hepatoprotective flavonoids from Scleromitron diffusum (Willd.) R.J. Wang with bio-enzymatic method against NAFLD by UPLC-MS/MS. Front Pharmacol. 2022;13:890148. doi:10.3389/fphar.2022.890148.

11. Olatunji TL, Adetunji AE, Olisah C, Idris OA, Saliu OD, Siebert F. Research progression of the genus Merremia: a comprehensive review on the nutritional value, ethnomedicinal uses, phytochemistry, pharmacology, and toxicity. Plants (Basel). 2021;10(10):2070. doi:10.3390/plants10102070.

12. Purwitasari N, Agil M. Metabolite profiling of extract and fractions of bidara upas (Merremia mammosa (Lour.) Hallier F.) tuber using UPLC-QToF-MS/MS. Biomed Pharmacol J. 2022;15:2025-41.

13. Purwitasari N, Agil M, Siswodihardjo S, Nidom RV. Bidara Upas (Merremia mammosa Hall) antiviral activity against SARS-CoV-2. J Med Chem Sci. 2023;6:3149-58. doi:10.26655/JMCHEMSCI.2023.12.28.

14. Hossain KN, Islam MS, Rahman SH, Sarker S, Mondal M, Rahman MA, et al. In vitro antioxidant and in vivo hepatoprotective properties of Wissadula periplocifolia extract. ACS Omega. 2023;8:47001-11. doi:10.1021/acsomega.3c06614.

15. Woo SM, Davis WD, Aggarwal S, Clinton JW, Kiparizoska S, Lewis JH. Herbal and dietary supplement induced liver injury: highlights from the recent literature. World J Hepatol. 2021;13:1019-41. doi:10.4254/wjh.v13.i9.1019.

16. Oscanoa TJ, Vidal X, Luque J, Julca DI, Romero-Ortuno R. Hepatotoxicity induced by isoniazid in patients with latent tuberculosis infection: a meta-analysis. Gastroenterol Hepatol Bed Bench. 2023;16:448-57. doi:10.22037/ghfbb.v16i1.2685.

17. Tong X, Wang Q, Zhao X, Sun Y, Wu X, Yang L, et al. Histological assessment based on liver biopsy: the value and challenges in NASH drug development. Acta Pharmacol Sin. 2022;43:1200-9. doi:10.1038/s41401-022-00874-x.

18. Fatima S, Kumari A, Dwivedi VP. Advances in adjunct therapy against tuberculosis: deciphering the emerging role of phytochemicals. MedComm (2020). 2021;2:494-513. doi:10.1002/mco2.82.

19. Huang X, Lowrie DB, Fan XY, Hu Z. Natural products in anti-tuberculosis host-directed therapy. Biomed Pharmacother. 2024;171:116087. doi:10.1016/j.biopha.2023.116087.

20. Patel-Rodrigues PA, Cundra L, Alhaqqan D, Gildea DT, Woo SM, Lewis JH. Herbal- and dietary-supplement-induced liver injury: a review of the recent literature. Livers. 2024;4:94-118. doi:10.3390/livers4010008.

21. Dimitrov S, Slavchev I, Simeonova R, Mileva M, Pencheva T, Philipov S, et al. Evaluation of acute and sub-acute toxicity, oxidative stress and molecular docking of two nitrofuranyl amides as promising anti-tuberculosis agents. Biomolecules. 2023;13(8):1174. doi:10.3390/biom13081174.

22. Ahmad F, Rani A, Alam A, Zarin S, Pandey S, Singh H, et al. Macrophage: a cell with many faces and functions in tuberculosis. Front Immunol. 2022;13:747799. doi:10.3389/fimmu.2022.747799.

23. Qiang L, Zhang Y, Lei Z, Lu Z, Tan S, Ge P, et al. A mycobacterial effector promotes ferroptosis-dependent pathogenicity and dissemination. Nat Commun. 2023;14. doi:10.1038/s41467-023-37148-x.

24. Amaral EP, Foreman TW, Namasivayam S, Hilligan KL, Kauffman KD, Bomfim CCB, et al. GPX4 regulates cellular necrosis and host resistance in Mycobacterium tuberculosis infection. J Exp Med. 2022;219:e20220504. doi:10.1084/jem.20220504.

25. Silwal P, Paik S, Kim JK, Yoshimori T, Jo EK. Regulatory mechanisms of autophagy-targeted antimicrobial therapeutics against mycobacterial infection. Front Cell Infect Microbiol. 2021;11:633360. doi:10.3389/fcimb.2021.633360.

26. Cubillos-Angulo JM, Nogueira BMF, Arriaga MB, Barreto-Duarte B, Araújo-Pereira M, Fernandes CD, et al. Host-directed therapies in pulmonary tuberculosis: updates on anti-inflammatory drugs. Front Med (Lausanne). 2022;9:970408. doi:10.3389/fmed.2022.970408.

27. Gautam S, Qureshi KA, Pasha SBJ, Dhanasekaran S, Aspatwar A, Parkkila S, et al. Medicinal plants as therapeutic alternatives to combat Mycobacterium tuberculosis: a comprehensive review. Antibiotics (Basel). 2023;12(3):541. doi:10.3390/antibiotics12030541.

28. Balkrishna A, Joshi M, Kabdwal M, Tomer M, Lochab S, Varshney A. Robust anti-tubercular profile of Solanum virginianum extract in enhancing isoniazid bioavailability and curtailing stress tolerance in Mycobacterium smegmatis. Front Microbiol. 2024;15:1429027. doi:10.3389/fmicb.2024.1429027.

29. Raqib R, Sarker P. Repurposed drugs and plant-derived natural products as potential host-directed therapeutic candidates for tuberculosis. Biomolecules. 2024;14(12):1497. doi:10.3390/biom14121497.

30. Di Giosia P, Stamerra CA, Giorgini P, Jamialahmadi T, Butler AE, Sahebkar A. The role of nutrition in inflammaging. Ageing Res Rev. 2022;77:101596. doi:10.1016/j.arr.2022.101596.

31. Wijesinghe TP, Dharmasivam M, Dai CC, Richardson DR. Innovative therapies for neuroblastoma: the surprisingly potent role of iron chelation in up-regulating metastasis and tumor suppressors and down-regulating the key oncogene, N-myc. Pharmacol Res. 2021;173:105889. doi:10.1016/j.phrs.2021.105889.

Downloads

Published

2026-09-30

How to Cite

Rachmaniyah, R., Darmanto, W., Winarni, D., Khambali, K., & Rokhmalia, F. (2026). Histopathological study of the effects of Decalobanthus mammosus extract on liver necrosis in a tuberculosis mouse model. Current Issues in Pharmacy and Medical Sciences, 39(3), 165-173. https://doi.org/10.12923/cipms-2026-0025

Similar Articles

1-10 of 329

You may also start an advanced similarity search for this article.